Q/C TECHNOLOGIES, INC. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On November 20, 2026, Q/C Technologies amended its Series G and Series H Convertible Preferred Stock certificates of designation with PharmaCyte Biotech, Inc., the majority holder. The amendments modified beneficial ownership limitations: PharmaCyte's conversion cap remains at 49.99%, but other holders' cap increased from 4.99% to 9.99%. Series G Long-Term Warrants were also amended to increase PharmaCyte's beneficial ownership cap from an unspecified prior level to 49.99%. Series H maturity date was extended to September 2, 2027, with provisions for further extension upon triggering events or fundamental transactions. PharmaCyte holds majority of both Series G and Series H preferred shares.
Why this rating
Capital structure amendments to preferred stock conversion limits and warrant terms. Beneficial to PharmaCyte as a major investor; minor operational impact. At $3.6M market cap, restructuring of preferred terms is administrative routine for a micro-cap company in distressed equity financing.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.